Two compounds prolonged the survival of photoreceptors in a retinitis pigmentosa mouse model for rod opsin misfolding ...

(Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvictotm (lutetium (177 Lu) vipivotide tetraxetan injection), a targeted radioligand therapy for adult patients ...

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that eligible patients in Ontario now have access to Pluvicto™ (lutetium (177Lu) vipivotide tetraxetan injection), a targeted ...

The list includes several groundbreaking therapies that are expected to change the treatment landscape for several diseases and conditions.

It's JPM 2025 and here at Fierce Biotech we’re bringing you all the latest updates live from the life sciences event of the ...

Anticipates multiple clinical updates in the next 12-18 months, including further progress from two ongoing clinical programs and initiation of ...

Andy Extance charts how research into revolutionary targeted protein degradation therapies is moving from serendipity to ...

Golfers at the Atlantic Beach Links, situated 700m from the beach in Melkbosstrand, Cape Town, were treated to a spectacular battle of wits between these species on Wednesday. In a video posted on the ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company and HBM Holdings Limited ("Harbour BioMed") (together with the Company, the "Licensors"), have entered into ...

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused ...

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the ...

Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 ...